We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+50.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$1.1B
AUM Growth
+$345M
Cap. Flow
+$47.4M
Cap. Flow %
4.29%
Top 10 Hldgs %
64.76%
Holding
67
New
13
Increased
15
Reduced
13
Closed
9
Avg Time Held Equity + Options
6.4 quarters
Top 10 Avg Time Held Equity + Options
4.4 quarters
Top 20 Avg Time Held Equity + Options
6.1 quarters
Avg Time Held Equity only
6.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
6.1 quarters

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$29.8M
2
IMMX icon
Immix Biopharma
IMMX
+$21.8M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$14.2M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$14.1M
5
VSTM icon
Verastem
VSTM
+$8.71M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$19.5M
2
HROW icon
Harrow
HROW
+$16.1M
3
SNWV icon
SANUWAVE Health Inc
SNWV
+$10.5M
4
JBIO icon
Jade Biosciences
JBIO
+$5.89M
5
LQDA icon
Liquidia Corp
LQDA
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LQDA icon
1
Liquidia Corp
LQDA
$2.4B
$195M 17.67%
2,447,500
-97,500
-4% -$5.23M
2021 Q4
18 quarters
ETON icon
2
Eton Pharmaceutcials
ETON
$1.52B
$104M 9.38%
2,860,000
– –
2018 Q4
30 quarters
HROW icon
3
Harrow
HROW
$1.06B
$102M 9.23%
2,400,000
-432,230
-15% -$16.1M
2018 Q3
31 quarters
IRON icon
4
Disc Medicine
IRON
$2.17B
$62.5M 5.66%
855,000
+434,000
+103% +$29.8M
2025 Q1
5 quarters
URGN icon
5
UroGen Pharma
URGN
$1.87B
$53M 4.8%
1,439,996
+9,996
+0.7% +$271K
2025 Q4
2 quarters
APGE icon
6
DELISTED
Apogee Therapeutics
APGE
$51.8M 4.69%
390,000
– –
2025 Q3
3 quarters
MGTX icon
7
MeiraGTx Holdings
MGTX
$955M
$48M 4.34%
3,550,000
+1,426,741
+67% +$14.2M
2025 Q4
2 quarters
SLGL icon
8
Sol-Gel Technologies
SLGL
$224M
$37.1M 3.36%
500,000
– –
2025 Q3
3 quarters
RZLT icon
9
Rezolute
RZLT
$446M
$32.8M 2.97%
6,300,000
– –
2024 Q3
7 quarters
TGTX icon
10
TG Therapeutics
TGTX
$8.32B
$29.4M 2.66%
535,000
– –
2023 Q3
11 quarters
IMMX icon
11
Immix Biopharma
IMMX
$720M
$24.2M 2.19%
+2,345,000
New +$21.8M
2026 Q2
0 quarters
CBIO icon
12
Crescent Biopharma
CBIO
$480M
$23.7M 2.15%
1,319,351
+6,736
+0.5% +$132K
2025 Q4
2 quarters
STOK icon
13
Stoke Therapeutics
STOK
$1.45B
$22.9M 2.07%
700,000
– –
2024 Q4
6 quarters
ACOG icon
14
Alpha Cognition
ACOG
$192M
$20.9M 1.89%
2,895,467
+333,517
+13% +$2.09M
2025 Q3
3 quarters
EWTX icon
15
Edgewise Therapeutics
EWTX
$3.94B
$20.3M 1.84%
500,000
– –
2022 Q1
17 quarters
RVMD icon
16
Revolution Medicines
RVMD
$40.4B
$18.7M 1.7%
100,000
– –
2025 Q2
4 quarters
GLUE icon
17
Monte Rosa Therapeutics
GLUE
$844M
$18M 1.63%
+745,000
New +$14.1M
2026 Q2
0 quarters
ALMS icon
18
Alumis Inc
ALMS
$849M
$15.5M 1.4%
550,000
– –
2025 Q2
4 quarters
CDXS icon
19
Codexis
CDXS
$145M
$15.3M 1.39%
6,785,000
– –
2014 Q1
49 quarters
REPL icon
20
Replimune Group
REPL
$1.14B
$15.3M 1.39%
+1,384,993
New +$8.47M
2026 Q2
0 quarters
XOMA icon
21
DELISTED
Xoma
XOMA
$14.4M 1.3%
338,374
+38,374
+13% +$1.56M
2017 Q1
37 quarters
MBX icon
22
MBX Biosciences
MBX
$2.36B
$14.4M 1.3%
260,000
– –
2025 Q1
5 quarters
RYTM icon
23
Rhythm Pharmaceuticals
RYTM
$5.96B
$13.6M 1.23%
122,500
-500
-0.4% -$45.2K
2022 Q2
16 quarters
EDIT icon
24
Editas Medicine
EDIT
$375M
$12.5M 1.13%
3,861,930
+1,934,933
+100% +$5.66M
2026 Q1
1 quarter
PTGX icon
25
Protagonist Therapeutics
PTGX
$8.96B
$12.3M 1.11%
100,000
– –
2023 Q4
10 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2026 Portfolio in Review

As of Q2 2026, Opaleye Management held 67 positions worth $1.1B, up 45% from $759M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $47.4M of net new capital in Q2 2026, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Immix Biopharma: 2,345,000 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Harrow, an estimated $16.1M trimmed.

  • Opaleye Management's largest Q2 2026 buy was Immix Biopharma: 2,345,000 shares worth $24.2M.
  • Opaleye Management added most to Disc Medicine in Q2 2026, an estimated $29.8M increase.
  • Opaleye Management's biggest Q2 2026 reduction was Harrow, cutting an estimated $16.1M.
  • Opaleye Management fully exited Perspective Therapeutics in Q2 2026, selling an estimated $19.5M.
  • Opaleye Management's ten largest holdings make up 65% of its $1.1B portfolio in Q2 2026.
  • Opaleye Management opened 13 new positions and closed 9 in Q2 2026.
  • Opaleye Management's portfolio value rose 45% quarter-over-quarter to $1.1B.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.